Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 251 participants.

Also called NCT03470545

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 251 participants (enrolled count) (from the registry)
Sponsor
MyoKardia, Inc. (from the registry)
Registry
  • NCT NCT03470545
Other papers using this trial's data
  • Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial Journal of medical economics, 2022 DOI, PubMed 34907813
  • Association Between age or Duration of Diagnosis in Obstructive Hypertrophic Cardiomyopathy and Response to Mavacamten Treatment: Exploratory Analysis of the EXPLORER-HCM Trial Journal of cardiac failure, 2025-06 DOI, PubMed 39653325
  • Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy Journal of the American College of Cardiology, 2021-12-21 DOI, PubMed 34915982
  • Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized Trial JAMA cardiology, 2023-03-01 DOI, PubMed 36652223, PMC9857843 In the PMC Open Access subset under CC BY-NC-ND.
  • Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet (London, England), 2020-09-12 DOI, PubMed 32871100 PubMed links an erratum for this paper. Erratum: PMID 32919516
  • Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Lancet (London, England), 2021-06-26 DOI, PubMed 34004177
  • The Kansas City Cardiomyopathy Questionnaire in Relation to New York Heart Association Class Journal of cardiac failure, 2025-02 DOI, PubMed 39349158, PMC11975531 In the PMC Open Access subset under CC BY-NC-ND.
  • The Psychometric Performance of the Kansas City Cardiomyopathy Questionnaire-12 in Symptomatic Obstructive Hypertrophic Cardiomyopathy Journal of cardiac failure, 2025-05 DOI, PubMed 39349160, PMC11975530 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, Czechia, Denmark, France, Germany, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03470545. Randomized; quadruple masking; primary purpose treatment. Start 2018-05-29 (actual); primary completion 2020-03-14 (actual). Results posted on 2021-10-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Acronym
EXPLORER-HCM
Condition
Obstructive Hypertrophic Cardiomyopathy
Intervention (Drug)
mavacamten
Intervention (Drug)
Placebo
Lead sponsor
MyoKardia, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03470545
Content hash
846e2466d7b01ced40d93a20436201a13d7f43868dc8c9243c0339cb11bd9a00